Valneva’s strategy stems from its vision to contribute to a world in which no one dies or suffers from a vaccine-preventable disease.
An integrated business model that has allowed to build a portfolio of differentiated assets as well as a robust commercial portfolio
- The Company is focused on utilizing its proven and validated product development capabilities to rapidly advance its late-stage clinical programs to regulatory approval and commercialization.
Investing in innovative R&D programs to meet unmet medical needs
- Valneva is focused on utilizing its proven and validated product development capabilities to rapidly advance solutions addressing unmet needs in infectious diseases towards regulatory approval, with the goal of becoming first-, best- or only-in-class, and commercialization.
Collaboration is often key to success in research and biotechnology
- Valneva has strategically entered into partnerships with other well-established pharmaceutical companies to leverage clinical and commercial capabilities to optimize the potential value of select assets.